Boston Scientific Corp. Wednesday said it expects single-digit revenue growth in the first quarter, but stronger momentum over the course of the full year.
The company forecast revenue in the first quarter from flat to 6% growth. On an organic basis, revenue will be between a 3% decline and a 3% gain compared with the year-ago quarter, the company forecast.
Boston Scientific guided for a profit in the first quarter of 5 cents a share to 11 cents a share, or 28 cents a share to 34 cents a share on an adjusted basis.
For the full year, the company said it expects revenue growth of 13% to 19% compared with 2020, or 12% to 18% on an organic basis. Its full year profit is expected to be 72 cents a share to 82 cents a share, or $1.50 a share to $1.60 a share on an adjusted basis, the company said.
The full-year guidance excludes the impact of Boston Scientific's acquisition of Preventice Solutions Inc.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.